Lupin to Showcase Phase 1 Findings of LNP3693 at ESMO 2025 Congress in Berlin

Lupin to Present Phase 1 Data on LNP3693 at ESMO 2025

Lupin Limited, a prominent player in the global pharmaceutical industry, is gearing up to present the findings from its Phase 1a clinical trial of LNP3693, a novel STING agonist, at the upcoming ESMO Congress 2025. This event will take place in Berlin, Germany, from October 17 to October 21, 2025, where the presentation titled 'A Phase 1 Dose Escalation Study of LNP3693 in Patients with Advanced or Metastatic Solid Tumors and Lymphoma' will be featured in the Investigational Immunotherapy session (Presentation Number 1553P).

The session is scheduled for October 19, 2025, from 09:00 to 17:00 CEST. Attendees can expect an in-depth examination of LNP3693's safety, pharmacokinetics, pharmacodynamics, and its preliminary anti-tumor activity among patients suffering from solid tumors.

Vinita Gupta, CEO of Lupin, expressed enthusiasm for sharing this data, stating, "This marks another important milestone for us. Following our successful presentation of LNP7457, a PRMT5 inhibitor, at ASCO in June 2025, it is a privilege to present the findings of another Phase 1 clinical trial for LNP3693, a STING agonist, at ESMO. ESMO's acknowledgment of the clinical research conducted in India underscores the proficiency of our team in oncology drug discovery, research, and clinical development."

About LNP3693

LNP3693 is an investigational injectable STING agonist designed to harness the body's immune response against cancer cells, particularly in patients with advanced solid tumors and various lymphomas. Utilizing STING (Stimulator of Interferon Genes) pathways has gained attention for its potential in cancer therapy, as these pathways play a crucial role in immune activation, leading to an increased immune response against tumors.

This presentation will provide vital qualitative insights into how LNP3693 performs regarding safety and its pharmacological effects, potentially illuminating future treatment paths for patients battling with hard-to-treat cancers.

Clinical Trials and Future Directions

The complete data set for this phase of study has already been prepared and will be formally addressed during the official session. According to the official guidelines, abstracts submitted and accepted for presentation at the ESMO Congress 2025 will be published online through the ESMO website starting from October 13, 2025.

Lupin's commitment to advancing oncology research is further illustrated by the registration number for this trial, CTRI/2023/10/059147, ensuring transparency and compliance within the pharma research framework.

About Lupin Limited

Lupin Limited, headquartered in Mumbai, India, is recognized for its innovative pharmaceutical products available in over 100 countries. The company focuses on developing a wide range of pharmaceutical applications, including branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. Their presence is particularly strong in therapeutic areas like respiratory health, cardiovascular issues, diabetes, and infectious diseases.

Lupin operates 15 advanced manufacturing facilities and has 7 dedicated research centers globally, supported by a workforce of more than 24,000 professionals. Committed to enhancing healthcare outcomes worldwide, Lupin continues to explore new avenues of research and development through its subsidiaries, including Lupin Diagnostics and Lupin Digital Health. For more information about Lupin, visit www.lupin.com.

Stay tuned for the presentation at ESMO 2025 to witness the unfolding innovations in cancer therapy spearheaded by Lupin Limited!